The subgroup analyses on the medications (pioglitazone, metformin and insulin) and diagnosis (MDD and bipolar depression) did not detect any clinical relevance of heterogeneity (Appendix A, Figure A1). The gene discussed is INS; the disease is bipolar disorder.